Immunic (IMUX) to Release Earnings on Thursday

Immunic (NASDAQ:IMUX) will issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect Immunic to post earnings of ($0.22) per share for the quarter.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same quarter in the prior year, the business earned ($0.54) earnings per share. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Stock Down 2.4 %

Shares of Immunic stock opened at $1.21 on Friday. The stock’s 50-day simple moving average is $1.50 and its 200-day simple moving average is $1.35. Immunic has a 52 week low of $0.95 and a 52 week high of $2.11. The company has a market capitalization of $109.00 million, a price-to-earnings ratio of -0.81 and a beta of 1.84.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Piper Sandler reissued an “overweight” rating and set a $28.00 price objective on shares of Immunic in a report on Tuesday, July 16th. B. Riley initiated coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target for the company. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners restated an “outperform” rating and set a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.